Key Points
- CEO Anhco Nguyen sold 2,915 shares on Nov. 17 at an average price of $13.19 for $38,448.85, trimming his stake by 4.29% to 64,974 shares (about $857k after the sale).
- Earnings beat: Atara reported quarterly EPS of ($0.32) versus consensus (‑$0.83) and revenue of $3.45M versus $2.74M expected.
- Shares jumped about 4.3% to $14.33 on light volume; the company has a market cap of ~$103.3M, a 52‑week range of $5.01–$18.70, and an analyst consensus of "Moderate Buy" with an average $21 price target, though Weiss reissued a "sell (d+)".
Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) CEO Anhco Nguyen sold 2,915 shares of the company's stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $13.19, for a total transaction of $38,448.85. Following the completion of the transaction, the chief executive officer owned 64,974 shares of the company's stock, valued at $857,007.06. This trade represents a 4.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Atara Biotherapeutics Stock Up 4.3%
Shares of NASDAQ:ATRA traded up $0.59 during midday trading on Thursday, reaching $14.33. 3,714 shares of the company were exchanged, compared to its average volume of 96,030. The firm has a market cap of $103.28 million, a PE ratio of 6.57 and a beta of 0.26. Atara Biotherapeutics, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $18.70. The stock has a fifty day simple moving average of $13.74 and a two-hundred day simple moving average of $11.07.
Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last released its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.51. Atara Biotherapeutics had a negative return on equity of 41.78% and a net margin of 15.40%.The firm had revenue of $3.45 million during the quarter, compared to analysts' expectations of $2.74 million. As a group, analysts forecast that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current year.
Institutional Trading of Atara Biotherapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the business. EcoR1 Capital LLC increased its holdings in shares of Atara Biotherapeutics by 7.7% during the 1st quarter. EcoR1 Capital LLC now owns 573,183 shares of the biotechnology company's stock worth $3,405,000 after acquiring an additional 41,049 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Atara Biotherapeutics by 6.6% during the third quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company's stock worth $2,915,000 after purchasing an additional 12,677 shares during the period. Staley Capital Advisers Inc. raised its position in shares of Atara Biotherapeutics by 60.0% in the first quarter. Staley Capital Advisers Inc. now owns 80,000 shares of the biotechnology company's stock valued at $475,000 after buying an additional 30,000 shares in the last quarter. Mackenzie Financial Corp boosted its stake in shares of Atara Biotherapeutics by 183.5% in the third quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company's stock valued at $914,000 after buying an additional 41,302 shares during the period. Finally, Geode Capital Management LLC increased its stake in Atara Biotherapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company's stock worth $464,000 after acquiring an additional 1,457 shares during the period. Institutional investors own 70.90% of the company's stock.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a "sell (d+)" rating on shares of Atara Biotherapeutics in a research report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $21.00.
Get Our Latest Stock Report on ATRA
About Atara Biotherapeutics
(
Get Free Report)
Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
